The Sensitivity Standard
The most technically differentiated and most misunderstood name in diagnostics.
This will be a "best ideas only" bio substack providing actionable, highly digestible and high conviction value to investors focused on quality not quantity. Disclaimer: Nothing in this article (or substack) is considered investment advice and is solely the opinion of the author.
*BOTN NTM Price Target at the end of the article*
The liquid biopsy market is about to bifurcate. On one side: the high-volume, broad-panel, targeted-gene-count assays that have dominated commercial oncology testing for the past five years. Think Guardant360, FoundationOne Liquid, the panel players that read a few hundred genes and report back actionable mutations for therapy selection. These are useful tests but they are also, increasingly, commoditizing. Price competition is intensifying and differentiation is narrowing as reimbursement rates are established but not expanding. On the other side: a smaller set of platforms attacking a completely different clinical problem with a fundamentally different technical approach. Not broad-panel therapy selection but ultra-sensitive, tumor-informed molecular residual disease detection.